NATURAL PRODUCT-BASED AMYLOID PROTEIN INHIBITORS
DOI:
https://doi.org/10.22159/ijs.2022.v10i1.41079Keywords:
Beta-carotene, Omega 3 fatty acids, Amyloid protein inhibitorsAbstract
Neurodegenerative disorders like Alzheimer’s are associated by plague formation of protein aggregates called amyloid proteins. Many natural-based products such as flavonoids, phenolic acids, iso-flavones, and polyunsaturated fatty acids play major role in therapeutic ability to degrade, slow down, and recondition the amyloid protein (amyloid protein inhibitors). These compounds extracted from plants have shown consequential potential in in vitro studies as well as in vivo studies. For requisite for brain nutritive growth, omega 3 fatty acids are important, whereas ß-carotene plays indispensable role in cognitive impairment and oxidative stress in the brain. It is described that omega 3 fatty acids are extracted from the source (flaxseed) by oil press method and ß-carotene is synthesized by physiochemical process from carrot. The main objective of this particular research topic is to provide more effectiveness in detaining the growth of amyloid protein inhibitors in brain. It is observed that the product with omega 3 and ß-carotene slow down the protein aggregation more efficiently than omega 3 capsules alone and intra-cerebroventricular injected streptozotocin. This can be determined by in silico activity of acetylcholinesterase. The analyses show extensive reciprocity between inhibitors and amyloid proteins. The administration of omega 3 with ß-carotene depreciates the amyloid protein aggregates more efficiently. Hence, it is suggested that the product can be used as treatment for neurodegenerative diseases like Alzheimer’s.
References
Velander P, Wu L, Henderson F, Zhang S, Bevan DR, Xu B. Natural product-based amyloid inhibitors. Biochem Pharmacol 2017;139:40-55.
Jicha GA, Markesbery WR. Omega-3 fatty acids: Potential role in the management of early Alzheimer’s disease. Clin Interv Aging 2010;5:45.
Avallone R, Vitale G, Bertolotti M. Omega-3 fatty acids and neurodegenerative diseases: New evidence in clinical trials. Int J Mol Sci 2019;20:4256.
Hira S, Saleem U, Anwar F, Sohail MF, Raza Z, Ahmad B. β-Carotene: A natural compound improves cognitive impairment and oxidative stress in a mouse model of streptozotocin-induced Alzheimer’s disease. Biomolecules 2019;9:441.
Yassine HN, Braskie MN, Mack WJ, Castor KJ, Fonteh AN, Schneider LS, Chui HC. Association of docosahexaenoic acid supplementation with Alzheimer disease stage in apolipoprotein Eε4 carriers: A Review. JAMA Neurolo 2017;74:339-47.
Bu XL, Rao PP, Wang YJ. Anti-amyloid aggregation activity of natural compounds: Implications for Alzheimer’s drug discovery. Mol Neurobiol 2016;53:3565-75.
Piva GS, Weschenfelder TA, Franceschi E, Cansian RL, Paroul N, Steffens C. Extraction and modeling of flaxseed (Linnum usitatissimum) oil using subcritical propane. J Food Eng 2018;228:50-6.
Dembitsky VM, Dzhemileva L, Gloriozova T, D’yakonov V. Natural and synthetic drugs used for the treatment of the dementia. Biochem Biophy Res Commun 2020;524:772-83.
Lei X, Yu J, Niu Q, Liu J, Fraering PC, Wu F. The FDA-approved natural product dihydroergocristine reduces the production of the Alzheimer’s disease amyloid-β peptides. Sci Rep 2015;5:16541.
Roth AD, Ramírez G, Alarcón R, von Bernhardi R. Oligodendrocytes damage in Alzheimer’s disease: Beta amyloid toxicity and inflammation. Biol Res 2005;38:381-7.
Findeis MA. Peptide inhibitors of beta amyloid aggregation. In: Current Topics in Medicinal Chemistry. Vol. 2. 2002. p. 417-23.
Park SY, Kim HS, Cho EK, Kwon BY, Phark S, Hwang KW, et al. Curcumin protected PC12 cells against beta-amyloid-induced toxicity through the inhibition of oxidative damage and tau hyperphosphorylation. Food Chem Toxicol 2008;46:2881-7.
Fiala M, Lau YC, Aghajani A, Bhargava S, Aminpour E, Kaczor- Urbanowicz KE, et al. Omega-3 fatty acids increase amyloid-β immunity, energy, and circadian rhythm for cognitive protection of Alzheimer’s disease patients beyond cholinesterase inhibitors. J Alzheimers Dis 2020;75:993-1002.
Porat Y, Abramowitz A, Gazit E. Inhibition of amyloid fibril formation by polyphenols: Structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des 2006;67:27-37.
Frydman-Marom A, Levin A, Farfara D, Benromano T, Scherzer- Attali R, Peled S, Ovadia M. Orally administrated cinnamon extract reduces β-amyloid oligomerization and corrects cognitive impairment in Alzheimer’s disease animal models. PLoS One 2011;6:e16564.
Belayneh HD, Wehling RL, Cahoon E, Ciftci ON. Extraction of omega- 3-rich oil from Camelina sativa seed using supercritical carbon dioxide. J Supercritical Fluids 2015;104:153-9.
Galimberti D, Scarpini E. Old and new acetylcholinesterase inhibitors for Alzheimer’s disease. Expert Opin Investig Drugs 2016;25:1181-87.
Ma L, Yang C, Zheng J, Chen Y, Xiao Y, Huang K. Non-polyphenolic natural inhibitors of amyloid aggregation. Eur J Med Chem 2020;192:112197.
Yiannopoulou KG, Papageorgiou SG. Current and future treatments for Alzheimer’s disease. Ther Adv Neurol Disord 2013;6:19-33.
Selkoe DJ. Amyloid protein and Alzheimer’s disease. Sci Am 1991;265:68-79.
Published
How to Cite
Issue
Section
Copyright (c) 2022 Suseem S R, Swagath
This work is licensed under a Creative Commons Attribution 4.0 International License.